Cover Image
市場調查報告書

囊狀纖維化症 (CF) :主要9個國家的市場預測

Cystic Fibrosis Forecast in 9 Major Markets 2015-2025

出版商 Black Swan Analysis 商品編碼 339845
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
囊狀纖維化症 (CF) :主要9個國家的市場預測 Cystic Fibrosis Forecast in 9 Major Markets 2015-2025
出版日期: 2015年08月01日 內容資訊: 英文 36 Pages
簡介

囊狀纖維化症 (CF) ,是影響身體整體分泌腺的一般染色體隱性疾病。

本報告提供全球主要9個國家(美國,法國,德國,義大利,西班牙,英國,巴西,日本,印度) 的囊狀纖維化症 (CF) 發病情形相關分析,提供您疾病概要和目前的患病人數,性別·各年代 (以五歲為區分) 的詳細情況,各地區·各民族趨勢,風險要素,疾病診斷與預後,主要的症狀和併發症,未來性的趨勢預測 (今後10年份) 等資訊,為您概述為以下內容。

圖表

簡介

疾病的原因

風險要素與預防法

疾病診斷

各地區/各民族的差異

疾病的預後與臨床經過

疾病相關的主要併發症/特徵

患者數的定量化技術

囊狀纖維化症 (CF) 的最大患病人數

  • 努力呼氣肺活量 (FEV)
  • 突然變異型的囊狀纖維化症 (CF)
  • 囊狀纖維化症 (CF) 的呼吸系統併發症
  • 囊狀纖維化症 (CF) 相關的其他併發症

簡稱

相關出版

患者基群線上資料庫

患者基群產品

價格的線上資料·平台

參考文獻

附錄

目錄
Product Code: CYSF0010815

Cystic Fibrosis (CF) is an autosomal-recessive disease which affects the secretory glands throughout the body. The disease primarily involves the lung, but can also affect other organs. This report provides the current prevalent population for CF across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of CF. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of CF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for CF include:

  • Respiratory complications
  • Gastrointestinal complications
  • Osteoporosis
  • Cirrhosis
  • Cystic Fibrosis Related Diabetes
  • Infertility

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global CF's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of CF and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on CF's prevalent population.
  • Identify sub-populations within CF which require treatment.
  • Gain an understanding of the specific markets that have the largest number of CF patients.

Coverage

US, UK, FR, DE, IT, ES, JP, BR, IN

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors and Prevention

Diagnosis of the Disease

Variation by Geography/ Ethnicity

Disease Prognosis and Clinical Course

Key Co-Morbid Conditions / Features associated with the Disease

Methodology for Quantification of Patient Numbers

Top-Line Prevalence for Cystic Fibrosis

  • Forced expiratory Volume (FEV)
  • Cystic Fibrosis with Mutation Type
  • Respiratory Complications of Cystic Fibrosis
  • Other Co-morbidities Regarding Cystic Fibrosis

Abbreviations used in the Report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Tables and Figures

  • Prevalence of CF, total (000s)
  • Prevalence of CF, males (000s)
  • Prevalence of CF, females (000s)
  • Forced Expiratory Volumes of CF Patients, total (000s)
  • Cystic Fibrosis Patients with Mutation type, total (000s)
  • Prevalence of Asthma in Patients with CF, total (000s)
  • Prevalence of Pneumonia in Patients with CF, total (000s)
  • Prevalence of CF Related Diabetes in Patients with CF, total (000s)
  • Prevalence of Pancreatic Insufficiency in Patients with CF ,total (000s)
  • USA Prevalence of CF by 5-yr age cohort, males (000s)
  • USA Prevalence of CF by 5-yr age cohort, females (000s)
  • France Prevalence of CF by 5-yr age cohort, males (000s)
  • France Prevalence of CF by 5-yr age cohort, females (000s)
  • Germany Prevalence of CF by 5-yr age cohort, males (000s)
  • Germany Prevalence of CF by 5-yr age cohort, females (000s)
  • Italy Prevalence of CF by 5-yr age cohort, males (000s)
  • Italy Prevalence of CF by 5-yr age cohort, females (000s)
  • Spain Prevalence of CF by 5-yr age cohort, males (000s)
  • Spain Prevalence of CF by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of CF by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of CF by 5-yr age cohort, females (000s)
  • Brazil Prevalence of CF by 5-yr age cohort, males (000s)
  • Brazil Prevalence of CF by 5-yr age cohort, females (000s)
  • Japan Prevalence of CF by 5-yr age cohort, males (000s)
  • Japan Prevalence of CF by 5-yr age cohort, females (000s)
  • India Prevalence of CF by 5-yr age cohort, males (000s)
  • India Prevalence of CF by 5-yr age cohort, females (000s)
Back to Top